	US 12,280,064 B2
	Calmodulin inhibitors for the treatment of ribosomal disorders and ribosomopathies
Leonard I. Zon, Wellesley, MA (US); and Alison M. Taylor, Cambridge, MA (US)
Assigned to CHILDREN'S MEDICAL CENTER CORPORATION
Filed by CHILDREN'S MEDICAL CENTER CORPORATION, Boston, MA (US)
Filed on Apr. 7, 2023, as Appl. No. 18/297,285.
Application 18/297,285 is a continuation of application No. 17/353,717, filed on Jun. 21, 2021, granted, now 11,654,149.
Application 17/353,717 is a continuation of application No. 16/538,293, filed on Aug. 12, 2019, granted, now 11,065,258, issued on Jul. 20, 2021.
Application 16/538,293 is a continuation of application No. 15/806,765, filed on Nov. 8, 2017, granted, now 10,420,778, issued on Sep. 24, 2019.
Application 15/806,765 is a continuation of application No. 14/385,524, granted, now 9,827,252, issued on Nov. 28, 2017, previously published as PCT/US2013/028969, filed on Mar. 5, 2013.
Claims priority of provisional application 61/611,751, filed on Mar. 16, 2012.
Claims priority of provisional application 61/611,845, filed on Mar. 16, 2012.
Prior Publication US 2024/0091238 A1, Mar. 21, 2024
Int. Cl. A61K 31/553 (2006.01); A61K 31/145 (2006.01); A61K 31/4184 (2006.01); A61K 31/4375 (2006.01); A61K 31/4418 (2006.01); A61K 31/495 (2006.01); A61K 31/4965 (2006.01); A61K 31/54 (2006.01); A61K 31/5415 (2006.01)

CPC A61K 31/553 (2013.01) [A61K 31/145 (2013.01); A61K 31/4184 (2013.01); A61K 31/4375 (2013.01); A61K 31/4418 (2013.01); A61K 31/495 (2013.01); A61K 31/4965 (2013.01); A61K 31/54 (2013.01); A61K 31/5415 (2013.01)]

9 Claims

1. A method of treating a subject with Diamond Blackfan Anemia (DBA), comprising administering an effective amount of a calmodulin inhibitor to the subject to decrease p53 or p21 in at least one of CD34+ cells, erythroid cells or erythroid differentiated cells in the subject, wherein the calmodulin inhibitor is N-(6-aminohexyl)-5-bromo-2-naphthalenesulfonamide.